Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen

Second- and third-generation drugs for immuno-oncology treatment—The more the better?

(2017) Wolfram C.M. Dempke et al.   EUROPEAN JOURNAL OF CANCER

New checkpoints in cancer immunotherapy

(2017) Ling Ni et al.   IMMUNOLOGICAL REVIEWS

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Learning from the “tsunami” of immune checkpoint inhibitors in 2015

(2016) Hampig Raphael Kourie et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

(2016) Paul E. Hughes et al.   TRENDS IN IMMUNOLOGY

Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy

(2015) Megan Cully   NATURE REVIEWS DRUG DISCOVERY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

(2013) Jérôme Galon et al.   JOURNAL OF PATHOLOGY

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells

(2013) Bastian Schilling et al.   PLoS One

IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients

(2012) B. Schilling et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

(2011) Neil L. Berinstein et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma

(2011) Theresa L. Whiteside et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer

(2011) Gregory T. Wolf et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction

(2011) Bernhard Mlecnik et al.   JOURNAL OF CLINICAL ONCOLOGY

IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model

(2011) Bastian Schilling et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Peptide Based Vaccine Approaches for Cancer—A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory Regimen

(2011) Paul H. Naylor et al.   Cancers

Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic

(2010) Malgorzata Czystowska et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IRX-2 increases the T cell-specific immune response to protein/peptide vaccines

(2010) Paul H. Naylor et al.   VACCINE

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death

(2009) M Czystowska et al.   CELL DEATH AND DIFFERENTIATION